Explore

TrendlineTrendline
BioAge Labs Reports Positive Phase 1 Trial Results for BGE-102 and Advances to Phase 2 for Cardiometabolic Diseases

BioAge Labs Reports Positive Phase 1 Trial Results for BGE-102 and Advances to Phase 2 for Cardiometabolic Diseases

BioAge Labs Reports Positive Phase 1 Trial Results for BGE-102 and Advances to Phase 2 for Cardiometabolic Diseases
TrendlineTrendline
Anaheim Bio Secures €40 Million Series A Funding to Advance Arthritis Treatment ANA-1

Anaheim Bio Secures €40 Million Series A Funding to Advance Arthritis Treatment ANA-1

Anaheim Bio Secures €40 Million Series A Funding to Advance Arthritis Treatment ANA-1
Rapid ReadRapid Read
Energy Drinks and Stimulant Supplements Linked to Acute Cardiovascular Events in Young Consumers

Energy Drinks and Stimulant Supplements Linked to Acute Cardiovascular Events in Young Consumers

New study results presented at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago indicate a disproportionate reporting of acute cardiovascular events associated with caffeine- and stimulant-containing energy drinks and dietary supplements. Investigators reviewed data from the U.S. Food and Drug Administration’s (FDA) Center for Food Safety and Applied Nutrition Adverse Event Reporting System. The analysis compared cardiovascular event reports for products containing caffeine, methylxanthines (like guarana and green tea extracts), sympathomimetics (such as yohimbine and ephedra), and popular caffeinated brands (including Celsius, Red Bull, Monster, and Rockstar) against other orally consumed products. The study found that 8 out of 10 cardiovascular outcomes achieved statistical signal thresholds, with the strongest signal for cardiac arrest, followed by myocardial infarction, ventricular arrhythmia, and palpitations. These findings suggest a significant link between these products and...
USA TodayUSA Today
Occasional marijuana use linked to higher stroke risk, study finds

Occasional marijuana use linked to higher stroke risk, study finds

A new study of nearly 443,000 US adults found a link between marijuana use, including occasional use, and higher odds of stroke and heart issues.
Rapid ReadRapid Read
MHRA Issues New Guidance on Non-OECD Clinical Trial Data Assessment to Support UK Research

MHRA Issues New Guidance on Non-OECD Clinical Trial Data Assessment to Support UK Research

The Medicines and Healthcare products Regulatory Agency (MHRA) has published new guidance detailing its patient-centered approach to assessing clinical trial applications that rely on non-clinical safety data generated outside the Organisation for Economic Co-operation and Development (OECD) Mutual Acceptance of Data framework. This guidance, issued on November 4, 2026, aims to support a more risk-proportionate approach to clinical research, thereby advancing the development of new treatments and increasing opportunities for UK patients to participate in trials. While data generated within the OECD framework remains the expected standard, the MHRA will now consider non-OECD data in individual applications, particularly when supported by evidence and the circumstances of the intended patient population.
TrendlineTrendline
Clinical Research Sites Face Growing Strain from Trial Complexity, AI Integration Challenges

Clinical Research Sites Face Growing Strain from Trial Complexity, AI Integration Challenges

Clinical Research Sites Face Growing Strain from Trial Complexity, AI Integration Challenges
Rapid ReadRapid Read
Antengene Initiates Phase I ATTRACT Study for Autoimmune Disease Treatment ATG-201 in China and Australia

Antengene Initiates Phase I ATTRACT Study for Autoimmune Disease Treatment ATG-201 in China and Australia

Antengene Corporation Limited, a global biotech company, has announced that the first patient has been dosed in China for its Phase I ATTRACT study. This study evaluates ATG-201, Antengene's proprietary CD19 × CD3 bispecific T-cell engager antibody (TCE), in adult patients suffering from B cell-mediated autoimmune diseases. The study is being conducted in both China and Australia, with ATG-201 having received approval from the Human Research Ethics Committee (HREC) in Australia and completing the Clinical Trial Notification (CTN) process with the Therapeutic Goods Administration (TGA). ATG-201 is designed to precisely target and eliminate CD19-expressing B cells using steric hindrance masking technology, aiming to leverage the body's immune system for treating these diseases. The ATTRACT study, led by Professor Zhanguo Li, will assess the safety, tolerability, and preliminary efficacy of ATG-201 in two parts: Dose Escalation (Part I) and Dose Expansion (Part II).
TrendlineTrendline
Pfizer Medical Director Discusses AI's Role in Bridging Clinical Trial Data to Real-World Application

Pfizer Medical Director Discusses AI's Role in Bridging Clinical Trial Data to Real-World Application

Pfizer Medical Director Discusses AI's Role in Bridging Clinical Trial Data to Real-World Application
TrendlineTrendline
Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline
Rapid ReadRapid Read
Peptilogics Enrolls First International Patient in RETAIN Trial for Prosthetic Joint Infection Treatment

Peptilogics Enrolls First International Patient in RETAIN Trial for Prosthetic Joint Infection Treatment

Peptilogics, a clinical-stage biotech company, has announced the enrollment of the first international patient in the pivotal RETAIN Phase 2/3 trial for zaloganan (PLG0206), a drug candidate designed to treat prosthetic joint infection (PJI). This enrollment took place in the U.K. at Leeds Teaching Hospitals NHS Trust and NIHR Clinical Research Facility: Leeds, marking the first patient outside the U.S. to join the study. Zaloganan is an investigational antimicrobial peptide engineered to target biofilm, the primary driver of serious infections across various implanted medical devices. PJI affects approximately two percent of joint replacements, leading to significant complications and often requiring multiple surgeries. The RETAIN trial is a randomized, double-blind, placebo-controlled study aiming to enroll approximately 240 patients across 50 sites in the U.S., U.K., and Australia.
TrendlineTrendline
Medical Experts Debate Egg Consumption's Health Impact Amidst Conflicting Research

Medical Experts Debate Egg Consumption's Health Impact Amidst Conflicting Research

Medical Experts Debate Egg Consumption's Health Impact Amidst Conflicting Research
Rapid ReadRapid Read
New Research Links Energy Drinks and Stimulant Supplements to Increased Heart Risks in Young Adults

New Research Links Energy Drinks and Stimulant Supplements to Increased Heart Risks in Young Adults

Preliminary research indicates a significant association between energy drinks, stimulant supplements, and serious heart problems in young adults. The study, which analyzed over 28,000 adverse event reports submitted to the Food and Drug Administration (FDA) between 2017 and 2025, found that cardiac arrest was reported approximately 11 times more often with energy drinks and stimulant supplements compared to non-stimulant products. Heart attacks were reported 4.5 times more frequently, and ventricular arrhythmias and palpitations about four times more often. Nearly 45% of these heart-related reports involved adults aged 18 to 34. These findings, to be presented at the American Heart Association (AHA) Scientific Sessions 2026, suggest that while occasional consumption might pose minimal risk for healthy individuals, regular use could lead to cardiovascular harm, especially given that some energy drinks contain up to three times more caffeine per fluid ounce than brewed coffee, alongside other stimulants lik...